FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899698006> ?p ?o ?g. }

• W2899698006 endingPage "1048" @default.
• W2899698006 startingPage "1045" @default.
• W2899698006 abstract "Leishmania guyanensis is the prevailing protozoa responsible for leishmaniasis in the Amazon ecoregion, which encompasses Brazil, Venezuela, Colombia, Peru, Bolivia, Suriname, Ecuador, and British and French Guiana.1Fagundes-Silva G. Romero G. Cupolillo E. et al.Leishmania (Viannia) naiffi: rare enough to be neglected?.Memórias do Instituto Oswaldo Cruz. 2015; 110: 797-800Google Scholar This species can cause localized, diffuse, or disseminated cutaneous leishmaniasis (CL).2Fernandes A. Pedroso R. Venazzi E. et al.American cutaneous leishmaniasis with unusual clinical presentation and response to treatment.Rev Inst Med Trop Sao Paulo. 2016; 58Google Scholar, 3Vries H. Reedijk S. Schallig H. Cutaneous leishmaniasis: recent developments in diagnosis and management.Am J Clin Dermatol. 2015; 16: 99-109Google Scholar The lattermost, characterized by the presence of 10 lesions or more in different body parts, is seldom observed. This variant involves lymphatic dissemination, and it is usually associated with other Leishmania species, such as Leishmania braziliensis, which represents a therapeutic challenge.3Vries H. Reedijk S. Schallig H. Cutaneous leishmaniasis: recent developments in diagnosis and management.Am J Clin Dermatol. 2015; 16: 99-109Google Scholar There are few studies on the treatment of leishmaniasis caused by L guyanensis, which leads to poor evidence, fleeting protocols, and a success rate of 50% to 60%. This fact becomes more worrisome when we consider the health of travelers, for the Amazon is one of the main destinations for ecotourism worldwide, and leishmaniasis is one of the dermatoses most frequently associated with tropical countries.4Berens-Riha N. Fleischmann E. Pratlong F. et al.Cutaneous leishmaniasis (Leishmania tropica) in a German tourist after travel to Greece.J Travel Med. 2009; 16: 220-222Crossref PubMed Scopus (17) Google Scholar, 5Bricaire F. Danis M. Gentilini M. Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit.Clin Infect Dis. 1995; 20: 542-548Google Scholar In January 2015, a 56-year-old man suffering from therapy-refractory leishmaniasis was referred to our department. He had several cutaneous ulcers with raised borders (Fig 1). Before that date, in November 2014, he had been medicated for 20 days with 15 mg/kg/d of N-methyl glucamine (Glucantime), due to a positive smear of his lesions. Consequently, we reintroduced the medication—at the same dose—for 30 days. He returned in March 2015, reporting musculoskeletal pain and asthenia with ulcerated lesions on his trunk. The direct smear test result was still positive, confirming the disease's activity. We hospitalized the patient and administered liposomal amphotericin B for 7 days (7 mg/kg). The clinical manifestations improved; nonetheless, he still presented lesions on his thorax. We performed a biopsy and a polymerase chain reaction test. Although the histopathologic examination of hematoxylin-eosin–stained tissue found a lymphohistiocytic inflammatory infiltrate and Leishmania amastigotes within macrophages (Fig 2), the polymerase chain reaction showed L guyanensis as the infecting protozoa. On April 14, we discharged the patient from the hospital and initiated intramuscular pentamidine, considering both the disease's activity and the infecting species. He received 300 mg every 72 hours for 9 days. On January 6, 2016, the disease progressed into the disseminated form, with 12 active lesions (Fig 3) and a positive skin smear. Hence, we introduced Glucantime (5 mg/kg/d). This approach consisted of cycles during which we medicated the patient with a daily ampoule—405 mg of pentavalent antimonial [Sb(V)]—for 10 days and then interrupted the medication for 7 days. After 3 cycles, we did not observe active lesions. In February, the patient returned with fewer remising patches (Fig 4). In April, he displayed noteworthy improvement, presenting hyperchromic patches on his chest and upper limbs. After 1 year, there was no sign of disease.Fig 4Hyperchromic patches with an atrophic hypochromic center on the chest. Fewer and remising skin lesions after 3 intercalated low-dose cycles of Glucantime.View Large Image Figure ViewerDownload Hi-res image Download (PPT) We presented the case of a patient with therapy-refractory disseminated CL caused by L guyanensis and successfully treated with intercalated low doses of Glucantime (5 mg/kg/d). Pentamidine is the first-line medication in countries in which L guyanensis prevails, and since 2017, this medication has been considered the best option for treating CL caused by L guyanensis in Brazil. However, no randomized trial has demonstrated its therapeutic superiority to antimonials, which remain the gold standard for disseminated CL.6Mitropoulos P. Konidas P. Durkin-Konidas M. New world cutaneous leishmaniasis: updated review of current and future diagnosis and treatment.J Am Acad Dermatol. 2010; 63: 309-322Abstract Full Text Full Text PDF PubMed Scopus (111) Google Scholar Moreover, the Amazon is a convergence area for various Leishmania, and although the species respond differently to each medication, antimonials are usually effective. Therefore, we initiated our treatment with Glucantime. Localized CL treatment consists of the parenteral daily administration of an antimonial for 20 days, at doses of 10 to 20 mg/kg/d. It can be reintroduced after 20 days, at the same dose, but for 30 days. If there is no remission, the physician can try second-line drugs, such as pentamidine and amphotericin B. Because our initial therapy failed and after the definition of the infectious species, we initiated the treatment with pentamidine. Later, we introduced liposomal amphotericin B and once again did not obtain remission. The lesions only responded to a novel treatment schedule, based on intercalated cycles of Glucantime. The absence of commercial return for neglected diseases, such as leishmaniasis, has resulted in scarce funding from both public sector agencies and the pharmaceutical industry.7Yamey G. Torreele E. The world’s most neglected diseases.Br Med J. 2002; 325 ([editorial]): 176-177Crossref PubMed Scopus (115) Google Scholar Thus, the development of therapies has been meager. Accordingly, strategies based on improving treatment schedules have been more satisfactory than the use of potential new chemical entities. The exact structure and mechanism of the actions of antimonials are not fully understood. Nonetheless, 2 main theories justify its antileishmanial activity. Whereas 1 theory defends that Sb(V) has an intrinsic role, the other advocates that the pentavalent form is a prodrug, which needs to be reduced to Sb(III) so it can exert its activity.8Haldar A.K. Sen P. Roy S. Use of antimony in the treatment of leishmaniasis: current status and future directions.Mol Biol Int. 2011; : 571242Google Scholar, 9Frézard F. Demicheli C. Ribeiro R. Pentavalent antimonials: new perspectives for old drugs.Molecules. 2009; 14: 2317-2336Google Scholar More than 80% of the Sb(V) is excreted through urine in 6 to 8 hours. Approximately 5% to 10% of the remaining medication is reduced to trivalent antimonial [Sb(III)], which remains in the organism for 24 to 72 hours.9Frézard F. Demicheli C. Ribeiro R. Pentavalent antimonials: new perspectives for old drugs.Molecules. 2009; 14: 2317-2336Google Scholar Some state that this form has a third space concentration, which would delay its clearance for more than 30 days after its administration.9Frézard F. Demicheli C. Ribeiro R. Pentavalent antimonials: new perspectives for old drugs.Molecules. 2009; 14: 2317-2336Google Scholar The toxicity of antimonials is greatly related to their trivalent presentation and the administered doses.10Oliveira L.F. Schubach A.O. Martins M.M. et al.Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.Acta Tropica. 2011; 118: 87-96Crossref PubMed Scopus (256) Google Scholar Sb(III) accumulates until a plateau is reached. After 10 days without medication, however, the serum rates of antimonials are minor.9Frézard F. Demicheli C. Ribeiro R. Pentavalent antimonials: new perspectives for old drugs.Molecules. 2009; 14: 2317-2336Google Scholar Hence, waiting 20 days to reintroduce the drug in case of disease activity is a questionable approach. Although some diseases respond to plateaus of medication, others react to peaks of therapy. Leishmaniasis, often treated as the second, may belong in the first group. By intercalating 10 days of Glucantime (5 mg/kg/d) with 7 days without medication, we did not allow the serum rates to decrease to an insignificant level, obtaining efficacy without the same toxicity. Therefore, we diminished the adverse effects and elevated adherence to treatment. Our patient had no complaints during the low-dosage cycles. This is the first case report, to our knowledge, to show that low doses of Glucantime succeeded in treating therapy-refractory disseminated CL caused by L guyanensis. We believe that randomized trials should be conducted to evaluate low, intermittent doses, leading to fewer adverse effects fewer expenses, without jeopardizing the leishmanicidal activity of antimonials." @default.
• W2899698006 created "2018-11-16" @default.
• W2899698006 creator A5022343722 @default.
• W2899698006 creator A5030020938 @default.
• W2899698006 creator A5035981214 @default.
• W2899698006 creator A5077528545 @default.
• W2899698006 creator A5090967869 @default.
• W2899698006 date "2018-11-01" @default.
• W2899698006 modified "2023-09-27" @default.
• W2899698006 title "Intercalated low doses of antimonials for disseminated cutaneous leishmaniasis caused by Leishmania guyanensis: A successful approach in Amazonas, Brazil" @default.
• W2899698006 cites W1965731781 @default.
• W2899698006 cites W1972659234 @default.
• W2899698006 cites W1976270189 @default.
• W2899698006 cites W1989306682 @default.
• W2899698006 cites W1994517371 @default.
• W2899698006 cites W2048941556 @default.
• W2899698006 cites W2050197274 @default.
• W2899698006 cites W2125483721 @default.
• W2899698006 cites W2277944293 @default.
• W2899698006 cites W2305168406 @default.
• W2899698006 doi "https://doi.org/10.1016/j.jdcr.2018.07.014" @default.
• W2899698006 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6232638" @default.
• W2899698006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30456283" @default.
• W2899698006 hasPublicationYear "2018" @default.
• W2899698006 type Work @default.
• W2899698006 sameAs 2899698006 @default.
• W2899698006 citedByCount "0" @default.
• W2899698006 crossrefType "journal-article" @default.
• W2899698006 hasAuthorship W2899698006A5022343722 @default.
• W2899698006 hasAuthorship W2899698006A5030020938 @default.
• W2899698006 hasAuthorship W2899698006A5035981214 @default.
• W2899698006 hasAuthorship W2899698006A5077528545 @default.
• W2899698006 hasAuthorship W2899698006A5090967869 @default.
• W2899698006 hasBestOaLocation W28996980061 @default.
• W2899698006 hasConcept C136764020 @default.
• W2899698006 hasConcept C16005928 @default.
• W2899698006 hasConcept C203014093 @default.
• W2899698006 hasConcept C2776555147 @default.
• W2899698006 hasConcept C2778048844 @default.
• W2899698006 hasConcept C2778338367 @default.
• W2899698006 hasConcept C2778702967 @default.
• W2899698006 hasConcept C2779121891 @default.
• W2899698006 hasConcept C2781092759 @default.
• W2899698006 hasConcept C3019824283 @default.
• W2899698006 hasConcept C41008148 @default.
• W2899698006 hasConcept C556039675 @default.
• W2899698006 hasConcept C71924100 @default.
• W2899698006 hasConcept C71928629 @default.
• W2899698006 hasConceptScore W2899698006C136764020 @default.
• W2899698006 hasConceptScore W2899698006C16005928 @default.
• W2899698006 hasConceptScore W2899698006C203014093 @default.
• W2899698006 hasConceptScore W2899698006C2776555147 @default.
• W2899698006 hasConceptScore W2899698006C2778048844 @default.
• W2899698006 hasConceptScore W2899698006C2778338367 @default.
• W2899698006 hasConceptScore W2899698006C2778702967 @default.
• W2899698006 hasConceptScore W2899698006C2779121891 @default.
• W2899698006 hasConceptScore W2899698006C2781092759 @default.
• W2899698006 hasConceptScore W2899698006C3019824283 @default.
• W2899698006 hasConceptScore W2899698006C41008148 @default.
• W2899698006 hasConceptScore W2899698006C556039675 @default.
• W2899698006 hasConceptScore W2899698006C71924100 @default.
• W2899698006 hasConceptScore W2899698006C71928629 @default.
• W2899698006 hasIssue "10" @default.
• W2899698006 hasLocation W28996980061 @default.
• W2899698006 hasLocation W28996980062 @default.
• W2899698006 hasLocation W28996980063 @default.
• W2899698006 hasLocation W28996980064 @default.
• W2899698006 hasOpenAccess W2899698006 @default.
• W2899698006 hasPrimaryLocation W28996980061 @default.
• W2899698006 hasRelatedWork W1972872885 @default.
• W2899698006 hasRelatedWork W2058019775 @default.
• W2899698006 hasRelatedWork W2061481440 @default.
• W2899698006 hasRelatedWork W2069955825 @default.
• W2899698006 hasRelatedWork W2078526653 @default.
• W2899698006 hasRelatedWork W2171723430 @default.
• W2899698006 hasRelatedWork W2175371704 @default.
• W2899698006 hasRelatedWork W2186152422 @default.
• W2899698006 hasRelatedWork W2334243247 @default.
• W2899698006 hasRelatedWork W2970243300 @default.
• W2899698006 hasVolume "4" @default.
• W2899698006 isParatext "false" @default.
• W2899698006 isRetracted "false" @default.
• W2899698006 magId "2899698006" @default.
• W2899698006 workType "article" @default.